Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C₂N Diagnostics (¡°C₂N¡±) that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including Alzheimer¡¯s disease (AD), may help patients receive a timely diagnosis and appropriate treatment. Collaborating with C₂N, Eisai Inc. will work to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment in clinical practice outside of clinical trial settings in the U.S. Blood-based assays could result in the development of new standards in clinical care that may enable timely and accurate diagnoses for people living with cognitive impairment.

The number of people with dementia is growing substantially; more than 55 million people worldwide are living with dementia, and this number is expected to increase to 78 million by 2030.¹ Accurate diagnosis remains a barrier to early and proper care management; research reviews estimate that between 40 and 60 percent of adults with probable dementia are undiagnosed.² Importantly, blood-based assays may be able to help identify which patients may benefit from therapy, and therefore may help streamline care and reduce healthcare spending. Early detection, diagnosis and treatment of dementia protects individuals against risks from delayed or missed diagnosis and allows individuals, their families and their caregivers to plan for the future as the condition progresses.²

The development and adoption of blood-based assays as simple diagnostic tools, in every day clinical practice is an important step in improving care for people in remote and underserved communities where access to the traditional diagnostic tools of positron emission tomography (PET) and lumbar punctures are not a viable option.

In collaboration with various partners, Eisai will engage in practical application of simple and less invasive diagnostic technologies and diagnostics for dementia, including blood tests, and will work to improve the medical environment in which people with dementia can receive appropriate treatment, thereby contributing to relieving anxieties of people living with dementia and their families around the world.

 

Media Inquiries:

Public Relations Department,

Eisai Co., Ltd.

+81-(0)3-3817-5120